Gülşah Akyol

Dr. Gülşah Akyol


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Turkish Journal of Trauma and Emergency Surgery
Verified
Journal Article
Open access
GAGülşah Akyol
Gülşah Akyol
LKLeylag Kaynar
Leylag Kaynar

17 August 2026 in Acta Haematologica Oncologica Turcica
Verified
Journal Article
Open access
PDF file
GAGülşah Akyol
Gülşah Akyol
HSHatice Aslan Sırakaya
Hatice Aslan Sırakaya
ŞÜŞerife Emre Ünsal
Şerife Emre Ünsal
Thromboembolic Risk and Survival Outcomes in Multiple Myeloma Patients Following Autologous Stem Cell Transplantation - Acta Haematologica Oncologica Turcica

26 August 2026 in Nigerian Journal of Clinical Practice
Verified
Journal Article
Open access
GAGülşah Akyol
Gülşah Akyol
MBM Baydar
M Baydar
MKM Keklik
M Keklik
AÜA Ünal
A Ünal
MÇM Çetin
M Çetin
LKL Kaynar
L Kaynar
Background: The investigation aimed to determine whether there has been an increase in the amount of stem cells discarded due to patient mortality resulting from COVID-19 infection in our apheresis unit. Records were reviewed to investigate whether there were any differences in stem cell discards before and after the COVID-19 pandemic period following 2015. Results: In both periods, products retrieved from patients with myeloma and non-Hodgkin lymphoma constituted the majority of discarded stem cells. The process of discarding 230 hematopoietic stem cell products that were discarded after 2015 involved a period of five years prior to the COVID-19 pandemic, during which half of the products were discarded, and the other half were discarded in the last 2.5 years of the pandemic. Over 90% of the discarded products were autologous stem cell products. Additionally, 43 patients had their products discarded due to mortality associated with COVID-19 infection. This number does not include those who passed away at home for unknown reasons or in cases where COVID-19 infection could not be confirmed. The disposal of a single hematopoietic stem cell product, including the cost of the collection bag and DMSO freezing, was approximately 5,000 Turkish Lira during that period. In our country, which has around 50 hematopoietic stem cell transplantation centers, if we assume an average of about 40 stem cell disposals per center, this would result in a total loss of approximately 10 million Turkish Lira (calculated as 5,000 TL x 40 x 50 centers = 10,000,000 TL). This figure does not account for personnel labor costs. Conclusion: Furthermore, this review suggests that, similar to previous observations, preserving stem cells for second transplants in patients with non-Hodgkin lymphoma and certain elderly myeloma patients may be unnecessary.

Verified
Journal Article
Open access
PDF file
ŞÜŞerife Emre Ünsal
Şerife Emre Ünsal
HAHilal Akalın
Hilal Akalın
BTBusra Tan
Busra Tan
GAGülşah Akyol
Gülşah Akyol
AKAslıhan Kiraz
Aslıhan Kiraz
Background: This study investigates the relationship between clinical and hematological parameters and sub-threshold positive findings in cases with suspected hematological malignancies subjected to Janus Kinase 2 (JAK2) V617F qPCR testing. Methods: Adult patients referred to the Medical Genetics Clinic from the Erciyes University Faculty of Medicine Hematology Department between 2022 and 2024 for JAK2 V617F analysis due to suspected hematological malignancy were evaluated in this retrospective, cross-sectional study. Registered data from 2394 patients were analyzed, and 173 cases with a JAK2 V617F allele burden below 0.1% but above the negative control value were included in the study. SPSS version 25.0 software was used for statistical analysis. Results: More than half of the patients (56.6%) had no definitive hematological diagnosis at initial testing, while 28.9% developed a hematological disorder during follow-up, including overt MPN in 13.3%. Significant differences across VAF groups were observed for leukocytosis (p = 0.004), neutrophilia (p = 0.030), and monocytosis (p = 0.024), with the highest frequencies in Group 3 (0.041–0.099%). ROC analyses identified closely clustered optimal cut-offs around 0.027–0.029%, whereas no independent predictor of higher sub-threshold allele burden emerged in multivariate analysis (p > 0.05). Conclusions: Even sub-threshold levels of the JAK2 V617F mutation may exhibit specific clinical manifestations and may be associated with constitutional symptoms and leukocytosis in particular. The study findings also showed a lower awareness of the JAK2 test in clinical practice, and that it is significantly employed in off-label cases. In order to accurately interpret low-allele-burden results, molecular findings must be evaluated in conjunction with hematological parameters and appropriate clinical indications. The findings underscore the importance of applying the JAK2 V617F PCR test selectively and based on clinical suspicion.

4 October 2024 in Medicina
Verified
Journal Article
Open access
PDF file
IAibrahim halil açar
ibrahim halil açar
MAMuzeyyen Aslaner Ak
Muzeyyen Aslaner Ak
GAGülşah Akyol
Gülşah Akyol
TKTaha Ulutan Kars
Taha Ulutan Kars
YIYildiz Ipek
Yildiz Ipek
BGBirol Guvenc
Birol Guvenc
Background and Objectives: Acute myeloid leukemia and myelodysplastic syndrome are both clonal hematologic malignancies that primarily affect older adults. Current treatments for AML/MDS are both limited in number and efficacy. This study aims to evaluate venetoclax-based therapies in AML/MDS, focusing on overall survival and recurrence-free survival rates, and to expand real-world data on its use. Materials and Methods: Clinical and laboratory data on patients with AML/MDS aged 18≥ treated with venetoclax between January 2019 and July 2022 were included. Survival analysis was calculated based on the period from 2019 to December 2023. Results: A total of 161 AML and 40 patients with MDS were included. The median age was 63.53 ± 15.30 years for AML and 70.12 ± 10.21 years for MDS. In both groups, over 55% are male. A total of 77.6% of patients with AML and 75% of patients with MDS received treatment prior to venetoclax. Venetoclax was administered in combination with azacitidine to 84.5% of AML and 67.5% of MDS. The relapse rate in AML is approximately 15%. Overall, the 2-year survival rate is 46% and 18.73 months. The overall CR/CRi rate for patients with AML is 49.1%, while for patients with MDS, it is 50%. The 2-year survival rate for patients with MDS is 52.7%. The 2-year RFS rate was 75.5% for AML and 90.9% for MDS. The relapse rate in AML is approximately 15%. The percentage of adverse events leading to treatment discontinuation among those with grade 3–4 toxicity is low; 26.7% for AML (n = 43) and 15% for MDS (n = 6). Conclusions: Our real-world data demonstrate that venetoclax has the potential to improve overall survival rates when used in combination with HMAs and supports its use in patients with AML/MDS.

Verified
Journal Article
Open access
PDF file
RYRecep Civan Yuksel
Recep Civan Yuksel
AKahmet safa Kaynar
ahmet safa Kaynar
HMHatice Metin
Hatice Metin
ŞTŞahin Temel
Şahin Temel
CÜCanan Baran Ünal
Canan Baran Ünal
MSMurat Sungur
Murat Sungur
Background/Objectives: Patients with hematologic malignancies represent a high-risk population requiring intensive care due to infections, organ failure, and treatment-related complications. Despite advances in oncologic therapies and intensive care management, mortality remains high. This study aimed to evaluate prognostic factors and clinical outcomes in critically ill patients with hematologic malignancies admitted to the intensive care unit (ICU). Methods: Adult patients (≥18 years) with hematologic malignancies who were admitted to a medical ICU and stayed for at least 48 h were retrospectively included. Demographic characteristics, laboratory parameters, and APACHE II, SOFA, EASIX, and HALP scores, as well as mortality and organ support requirements, were evaluated. Results: A total of 108 patients were included. The median age was 61 years (IQR: 49–70), and 61% were male. The 28-day mortality was 64.8%. Overall, 83.3% of patients required invasive mechanical ventilation for at least 24 h. The median ICU length of stay was 5 days (IQR: 3–10). Median APACHE II and SOFA scores were 22 (IQR: 16–28) and 9 (IQR: 6–11), respectively. In multivariate analysis, SOFA score (OR: 1.218, 95% CI: 1.022–1.451) and the highest BUN level during ICU stay (OR: 1.034, 95% CI: 1.008–1.060) were independently associated with intubation. Admission creatinine level was the only independent predictor of renal replacement therapy (OR: 1.948, 95% CI: 1.081–3.510). APACHE II score was the only variable independently associated with 28-day mortality (OR: 1.064, 95% CI: 1.002–1.129). Conclusions: APACHE II showed a modest but statistically significant association with 28-day mortality in this cohort. Intubation and RRT requirements were mainly associated with organ dysfunction severity and renal impairment. Larger multicenter studies are needed to validate these findings and to better define risk stratification in critically ill hematologic patients.